Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model

Jong, Gabie de; Hendriks, T.; Franssen, Gerben M.; Oyen, Wim J.G.; Boerman, Otto C.; Bleichrodt, Robert P.

doi:10.1016/j.ejso.2010.12.009

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,4,8 Several strategies have been explored with an aim to improve the therapeutic efficacy of RIT for solid tumors, for example, application of the pretargeting technique, novel isotope, and combination with chemotherapy, and radiofrequency ablation (RFA). 5,[7][8][9][10][11][12][13] Fortunately, combination therapies by coupling or sequencing RIT with surgical excision, conventional cytotoxic chemotherapy, and RFA are likely to reflect potential clinical perspective for solid tumors. 2,6,14 In a word, no matter which strategy is used, the application of RIT aims to achieve a higher ratio of tumor-to-normal tissue (T/NT) of RIT agents, which might result in an anticipatory therapeutic response.…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3] However, for treating solid cancers, the results of both preclinical studies and clinical trials with RIT have still been modest. [4][5][6][7][8] The unsatisfactory therapeutic response of solid tumor RIT mainly attributes to the limited penetration or poor targeting capability, undesirable tumor radiosensitivity, and inadequate dose for consideration of excessive hematopoietic toxicity. 2,4,8 Several strategies have been explored with an aim to improve the therapeutic efficacy of RIT for solid tumors, for example, application of the pretargeting technique, novel isotope, and combination with chemotherapy, and radiofrequency ablation (RFA).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor

Zheng

Lu³

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Purpose: This study was aimed to investigate whether the tumor necrosis induced by radiofrequency ablation (RFA) can improve the ratio of tumor-to-normal tissue (T/NT) after intratumoral injection of 131 I-chTNT. Materials and Method: Eighteen New Zealand rabbits bearing VX 2 tumor on the thigh were randomly divided into two treatment groups (control group: intratumoral injection of 131 I-chTNT alone; RFA group: RFA + intratumoral injection of 131 I-chTNT 3 days after RFA) and each group was further divided into three subgroups I, II, and III (1-2 cm, 2-3 cm, and 3-4 cm in maximum diameter, respectively), by the tumor size. SPECT was performed to evaluate the T/NT on days 1, 8, and 15 after 131 I-chTNT injection. Results: After treatment, all rabbits underwent the SPECT whole-body scan and the T/NT was analyzed. The results showed that T/NT in the RFA group (55.45 -41.83) was significantly higher compared with the control group (7.23 -5.61) (F = 18.89, p = 0.001). Meanwhile, a linear ascending trend was found for T/NT in the RFA group along with the follow-up time (r = 0.47, p = 0.01). The tumor size or the dose of 131 I-TNT injection had no significant effect on the variation of T/NT in both groups ( p > 0.05). Conclusion: RFA before intratumoral injection of 131 I-chTNT can dramatically improve T/NT, demonstrating the potential application of this combination therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor

Zheng

Lu³

et al. 2013

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

show abstract

Combination treatments of tumors with thermoablation: principles and review of preclinical studies

Stransky-Heilkron

Humbert-Mehier²,

Allémann

2012

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

The Safety and Treatment Response of Combination Therapy of Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study In Vivo

Zheng

Guo

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

ObjectionTo investigate the safety and treatment response of radioimmunotherapy (RIT) in combination with radiofrequency ablation (RFA) for the treatment of VX2 tumor on rabbit.Materials and MethodsA total of 36 rabbits bearing VX2 tumor on the thigh were randomly assigned into 3 groups (group I: 1–2 cm; group II: 2–3 cm; group III: 3–4 cm) and 4 subgroups (A: as control, just puncture the tumor using the RFA electrode without power output; B: RFA alone; C: 131I-chTNT intratumoral injection alone; D: RFA+131I-chTNT intratumoral injection 3 days later). The variation of blood assay, weight and survival among different groups and subgroups were used to assess the treatment safety. Ultrasound (US) was used to monitor and assess the tumor response after treatment.ResultsAccording to the results of the weight and the blood assay among different groups, subgroups, and at two time points (one day before and the 16th day after treatment), no damages to the liver, kidney function and myelosuppression resulting from the treatment were found. No significant differences in survivals among the four subgroups (p = 0.087) were found. In addition, 131I-chTNT did not show significant inhibition effect on VX2 tumor progression according to US measurements.Conclusion 131I-chTNT intratumoral injection alone or in combination with RFA is relatively safe for rabbit without significant toxicity and shows no significant effect on the survival. The treatment response is not as satisfactory as anticipated.

show abstract

Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model

Cited by 3 publications

References 26 publications

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor

Combination treatments of tumors with thermoablation: principles and review of preclinical studies

The Safety and Treatment Response of Combination Therapy of Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study In Vivo

Contact Info

Product

Resources

About

Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model

Cited by 3 publications

References 26 publications

Radiofrequency Ablation Before Intratumoral Injection of 131I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX2 Tumor

Radiofrequency Ablation Before Intratumoral Injection of 131I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX2 Tumor

Combination treatments of tumors with thermoablation: principles and review of preclinical studies

The Safety and Treatment Response of Combination Therapy of Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study In Vivo

Contact Info

Product

Resources

About

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor

Radiofrequency Ablation Before Intratumoral Injection of ¹³¹I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX₂ Tumor